Brit J Cancer:绝经前和绝经后妇女内源性激素与浸润性乳腺癌风险的关系

2021-04-18 MedSci原创 MedSci原创

该研究证实了睾酮、IGF-1和SHBG与乳腺癌风险之间存在关联,并且睾酮水平对乳腺癌的影响因绝经状态而异。

一些内源激素与乳腺癌风险相关,但这些相关性的性质尚不完全明确。

近日,肿瘤学领域权威杂志British Journal of Cancer上发表了一篇研究文章,研究人员使用了UK生物库,测量了2006至2010年期间收集的血清中激素的浓度,并在2012–2013年期间重复的子样本(N=5000)中测量了激素浓度。研究人员通过数据链接确定了癌症发生率。研究人员采用了Cox回归模型进行分析,获取了校正回归稀释偏倚的风险比(HRs)。

在7.1年的中位随访期间,在30565名绝经前和133294名绝经后女性中,分别有527名和2997名女性被诊断为浸润性乳腺癌。绝经后妇女的癌症风险与睾酮水平呈正相关(每增加0.5 nmol/L的HR为1.18;95%CI:1.14、1.23),而在绝经前妇女中则不然(P=0.03)。

此外,浸润性乳腺癌与IGF-1(胰岛素样生长因子-1)相关(绝经前妇女每增加5 nmol/LHR为1.18; 1.02,1.35;绝经后妇女为1.07; 1.01,1.12;P=0.2),并且其与SHBG(性激素结合球蛋白)水平呈负相关(绝经前妇女每升高30 nmol/L的HR为0.96; 0.79,1.15,绝经后妇女为0.89; 0.84,0.94;P=0.4)。雌二醇仅在绝经前妇女中进行了评估,其与乳腺癌风险无关,但该激素存在研究局限性。

由此可见,该研究证实了睾酮、IGF-1和SHBG与乳腺癌风险之间存在关联,并且睾酮水平对乳腺癌的影响因绝经状态而异。

原始出处:

Sandar Tin Tin.et al.Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank.Brit J Cancer.2021.https://www.nature.com/articles/s41416-021-01392-z

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-04-22 科研科研科研

    激素与乳腺癌的风险

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2022-03-01 sjq027
  7. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1636030, encodeId=737e163603069, content=<a href='/topic/show?id=b87ce888080' target=_blank style='color:#2F92EE;'>#绝经前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78880, encryptionId=b87ce888080, topicName=绝经前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e8e22571454, createdName=ms5768352621950538, createdTime=Thu Jul 01 14:09:29 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770334, encodeId=f8551e7033483, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sat Jun 05 15:09:29 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820452, encodeId=01381820452f6, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Sat Nov 06 00:09:29 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682050, encodeId=5407168205004, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Aug 13 18:09:29 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959430, encodeId=110a959430fe, content=激素与乳腺癌的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Thu Apr 22 16:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062004, encodeId=d12d20620042a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Mar 01 06:09:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257267, encodeId=51dc125e26733, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286411, encodeId=a9c1128641149, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332026, encodeId=af7a13320267d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461264, encodeId=098f14612643d, content=<a href='/topic/show?id=4ebd65e084e' target=_blank style='color:#2F92EE;'>#浸润性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65708, encryptionId=4ebd65e084e, topicName=浸润性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ec6409669, createdName=xuyu, createdTime=Tue Apr 20 10:09:29 CST 2021, time=2021-04-20, status=1, ipAttribution=)]

相关资讯

AJOG:阴道雌激素治疗绝经后膀胱过度活动症(OAB)

膀胱过度活动症(OAB)是一种以尿急症状为特征的症候群,常伴有尿频和夜尿症状,可伴或不伴有急迫性尿失禁。OAB在中国的患病率为15.1%,比糖尿病(6%)更常见。大大降低了中老年女性的生活质量。

Hypertension:血压对绝经前后女性新发房颤的影响存在差异

血压升高,尤其是收缩压升高是绝经前妇女新发房颤的重要危险因素。绝经后妇女血压和新发房颤风险之间的相关性明显减弱。收缩压升高对未服用降压药物的妇女新发房颤的影响更深远。

Lancet Oncol:绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优

多项重要的随机临床研究已经证实,内分泌联合靶向治疗用于绝经后HR+/HER2-患者一线或二线治疗,可以带来显着的获益。鉴于此,目前所有主要的国际指南均推荐内分泌为基础的序贯方案应该作为优选方案,除非患者合并内脏危象。然而真实世界数据显示,一线化疗仍然非常常见,即使患者没有合并内脏危象。近日发布在《柳叶刀·肿瘤》(Lancet Oncology)的一项大型网络荟萃分析,系统性评估对比了内分泌治疗和化

JAMA Netw Open:降低绝经后女性髋部骨折风险的日常生活小妙招——轻度活动与步行

对于绝经后女性而言,预防骨折尤其是髋部骨折风险是非常重要的一件事情。那么,日常生活中,有哪些小举措有助于实现这一点?近期,一项最新研究发现,定期每周进行适度体育锻炼如户外劳动和步行有助于降低老年女性总体及髋部骨折风险。

Hum Reprod:早绝经的女士更易患慢病!澳大利亚研究称,更年期后半数女性有慢病

澳大利亚研究发现,一半的女性在更年期后患了慢病,而且更年期提前(≤40 岁)的女性患慢性病的风险更高。

JAMA:绝经后激素干预对女性乳腺癌发病率及死亡率的影响

长期随访发现,对于子宫切除的绝经后女性,接受结合雌激素可降低乳腺癌发病率和死亡率,但对于保留子宫的参与者,激素干预会增加乳腺癌发病率